Prof. Dr. Hadiye Derya DURANYILDIZ

Yayın Ağı

Makaleler 89

1. Biochemical Changes in Prostate Cancer: FMNL1 and PAK1 in Plasma and Urine

Bilgin Doğru E., Erdem S., Oğuz Soydinç H., İribaş Çelik A., Duranyıldız H. D.

Current Issues in Molecular Biology , cilt.47, sa.8, 2025 (SCI-Expanded, Scopus)

2. Do Salivary Cullin7 Gene Expression and Protein Levels Provide Advantages over Plasma Levels in Diagnosing Breast Cancer?

Tilgen Yasasever C., Duranyıldız H. D., Bademler S., Oğuz Soydinç H.

Current Issues in Molecular Biology , cilt.47, sa.19, ss.1-13, 2025 (Hakemli Dergi)

3. Can serum matrix metalloproteinase-9 and SMAD-2 levels predict lamina propria invasion in bladder urothelial carcinoma?

Yitgin Y., Erdem S., Serilmez M., Duranyıldız D., Verep S., Gasimov K., et al.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , sa.8, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

4. Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma.

Çavuş B., Akyuz F., İliaz R., Akyuz U., Duranyıldız D., Serilmez M., et al.

Experimental oncology , cilt.42, sa.3, ss.208-214, 2020 (Scopus) Sürdürülebilir Kalkınma

5. Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?

Erturk K., Karaman S., Dagoglu N., Serilmez M., Duranyildiz D., Tas F.

WIENER KLINISCHE WOCHENSCHRIFT , sa.17-18, ss.419-426, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy

Serilmez M., Ozgur E., Karaman Ş., Gezer U., Duranyildiz D.

CANCER BIOMARKERS , sa.2, ss.177-184, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. The biological role of LYVE-1 in lung cancer

Serilmez M., Karaman S., Soydinc H., Ozgur E., Duranyildiz D.

FEBS OPEN BIO , cilt.8, ss.318, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma

8. Clinical significance of serum leptin level in patients with gastric cancer

Tas F., Karabulut S., Erturk K., Duranyildiz D.

EUROPEAN CYTOKINE NETWORK , cilt.29, sa.2, ss.52-58, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Significance of serum neural precursor cell-expressed developmentally downregulated protein 9 in melanoma

Erturk K., Tas F., Serılmez M., Bilgin E., Duranyıldız D.

MOLECULAR AND CLINICAL ONCOLOGY , cilt.8, sa.1, ss.204-208, 2018 (ESCI, Scopus)

10. Serum Glypican-3, Vascular Endothelial Growth Factor, and lnterleukin-6 Levels in Hepatocellular Carcinoma

Serilmez M., Akyuz F., Ormeci Ciftcibasi A., Karabulut S., Kaymakoglu S., Yasasever V., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.33, sa.1, ss.18-27, 2018 (ESCI)

11. Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma

Iliaz R., Akyuz U., Tekin D., Serilmez M., Evirgen S., Cavus B., et al.

Arab Journal of Gastroenterology , cilt.17, sa.4, ss.164-167, 2016 (SCI-Expanded, Scopus)

12. Effect of intraperitoneal cetuximab administration on colonic anastomosis and early postoperative adhesion formation in a rat model

Kurt A., Karanlik H., Soylu S., Ozgur I., Soydinc H. O., Duranyildiz D., et al.

TURKISH JOURNAL OF SURGERY , cilt.32, sa.3, ss.157-161, 2016 (ESCI)

13. Clinical significance of serum claudin-1 levels in melanoma patients

Tas F., Bilgin E., Erturk K., Duranyildiz D.

MELANOMA RESEARCH , cilt.26, sa.4, ss.377-381, 2016 (SCI-Expanded, Scopus)

14. Clinical significance of serum laminin and type-IV collagen levels in cutaneous melanoma patients

Tas F., Bılgın E., Karabulut S., Duranyıldız D.

MOLECULAR AND CLINICAL ONCOLOGY , cilt.5, sa.1, ss.195-200, 2016 (ESCI, Scopus)

15. Circulating serum levels of angiopoietin-1 and angiopoietin-2 in nasopharynx and larynx carcinoma patients

Guveli M. E., Duranyildiz D., Karadeniz A., Bilgin E., Serilmez M., Soydinc H. O., et al.

TUMOR BIOLOGY , cilt.37, sa.7, ss.8979-8983, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma

Tas F., Bilgin E., Karabulut S., Erturk K., Duranyildiz D.

BBA CLINICAL , cilt.5, ss.166-169, 2016 (ESCI, Scopus) Sürdürülebilir Kalkınma

17. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer

Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.

BIOMEDICAL REPORTS , cilt.4, sa.5, ss.609-614, 2016 (ESCI, Scopus) Sürdürülebilir Kalkınma

18. Clinical significance of serum caveolin-1 levels in melanoma patients

Tas F., Karabulut S., Yasasever C. T., Duranyildiz D.

INTERNATIONAL JOURNAL OF DERMATOLOGY , cilt.55, sa.5, ss.558-562, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Clinical significance of serum laminin levels in patients with lung cancer

Tas F., Bilgin E., Tastekin D., Erturk K., Duranyildiz D.

BIOMEDICAL REPORTS , cilt.4, sa.4, ss.485-488, 2016 (ESCI, Scopus) Sürdürülebilir Kalkınma

20. Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients

Tas F., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICAL REPORTS , cilt.4, sa.4, ss.489-492, 2016 (ESCI, Scopus) Sürdürülebilir Kalkınma

21. Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

Tas F., Bılgın E., Karabulut S., Tastekın D., Duranyıldız D.

MOLECULAR AND CLINICAL ONCOLOGY , cilt.4, sa.4, ss.655-659, 2016 (ESCI, Scopus) Sürdürülebilir Kalkınma

22. Clinical significance of interleukin-4 and interleukin-18 levels in aggressive non-Hodgkin's lymphoma patients

Soydinc H., Guney N., Basaran M., Duranyildiz D., Yasasever V.

GENETICS AND MOLECULAR RESEARCH , cilt.15, sa.3, 2016 (SCI-Expanded)

23. Clinical significance of serum protease activated receptor1 levels in patients with lung cancer

Erturk K., Tastekin D., Bilgin E., Tas F., Disci R., Duranyildiz D.

European Review for Medical and Pharmacological Sciences , cilt.20, sa.2, ss.243-249, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

24. Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer

Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.77, sa.1, ss.127-131, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer.

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine , cilt.36, sa.3, ss.2097-103, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

26. Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY , cilt.70, ss.19-23, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

27. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma

Sen F., Yildiz I., Odabas H., Tambas M., Kilic L., Karadeniz A., et al.

TUMOR BIOLOGY , cilt.36, ss.1039-1044, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

28. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.

Kilic L., Yildiz I., Sen F. K., ERDEM M. G., Serilmez M., Keskin S., et al.

Cancer biomarkers : section A of Disease markers , cilt.15, sa.4, ss.405-11, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

29. Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables

Tas F., Yasasever C. T., Karabulut S., Tastekin D., Duranyildiz D.

Biomedicine and Pharmacotherapy , cilt.69, ss.237-241, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer

Tas F., Bilgin E., Karabulut S., Duranyildiz D.

CYTOKINE , cilt.71, sa.1, ss.66-70, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

31. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer

Tas F., Karabulut S., Duranyildiz D.

MOLECULAR AND CELLULAR BIOCHEMISTRY , cilt.396, ss.307-312, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

32. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

MELANOMA RESEARCH , cilt.24, sa.5, ss.475-479, 2014 (SCI-Expanded, Scopus)

33. Clinical significance of serum M30 and M65 levels in patients with breast cancer

Tas F., Karabulut S., Yildiz I., Duranyildiz D.

BIOMEDICINE & PHARMACOTHERAPY , cilt.68, sa.8, ss.1135-1140, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

34. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer

Tas F., Karabulut S., Bilgin E., Tastekin D., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.9, ss.9303-9309, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

35. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy

Tas F., Karabulut S., Bilgin E., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.8, ss.7871-7875, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

36. Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma

Tas F., Karabulut S., Yasasever C., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.7, ss.7233-7237, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

37. Clinical significance of serum tenascin-C levels in breast cancer

Tastekin D., Tas F., Karabulut S., Duranyildiz D., Serilmez M., Guveli M., et al.

TUMOR BIOLOGY , cilt.35, sa.7, ss.6619-6625, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

38. Coagulation tests show significant differences in patients with breast cancer

Tas F., Kilic L., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.6, ss.5985-5992, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

39. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy

Tas F., Karabulut S., Ciftci R., Sen F., Sakar B., Disci R., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.73, sa.6, ss.1163-1171, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

40. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.4, ss.3125-3132, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

41. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.4, ss.3095-3102, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

42. Clinical significance of serum transforming growth factor-beta 1 (TGF-beta 1) levels in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.4, ss.3611-3616, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

43. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

TUMOR BIOLOGY , cilt.35, sa.4, ss.3327-3331, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

44. Clinical significance of serum circulating insulin-like growth factor-1 (IGF-1) mRNA in hepatocellular carcinoma

Karabulut S., Duranyildiz D., Tas F., Gezer U., Akyuz F., Serilmez M., et al.

TUMOR BIOLOGY , cilt.35, sa.3, ss.2729-2739, 2014 (SCI-Expanded, Scopus)

45. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer

Tas F., Karabulut S., Serilmez M., Ciftci R., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.73, sa.3, ss.631-637, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

46. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer

Ciftci R., Tas F., Yasasever C., Aksit E., Karabulut S., Sen F., et al.

Tumor Biology , cilt.35, sa.7, ss.6941-6948, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

47. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma

Tas F., Karabulut S., Bilgin E., Sen F., Yildiz I., Tastekin D., et al.

TUMOR BIOLOGY , cilt.34, sa.6, ss.3529-3536, 2013 (SCI-Expanded, Scopus)

48. Clinical significance of serum M30 and M65 levels in melanoma

Tas F., Karabulut S., Serilmez M., Yildiz I., Sen F., Ciftci R., et al.

MELANOMA RESEARCH , cilt.23, sa.5, ss.390-395, 2013 (SCI-Expanded, Scopus)

49. Serum M65 as a Biomarker for Metastatic Renal Cell Carcinoma

Yildiz I., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., et al.

CLINICAL GENITOURINARY CANCER , cilt.11, sa.3, ss.290-296, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma

50. Clinical and prognostic significance of coagulation assays in lung cancer

Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.

RESPIRATORY MEDICINE , cilt.107, sa.3, ss.451-457, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

51. For Which Cancer Types can Neuron-Specific Enolase be Clinically Helpful in Turkish Patients?

Bilgin E., Dizdar Y., Serilmez M., Soydinc H. O., Yasasever C., Duranyildiz D., et al.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.14, sa.4, ss.2541-2544, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

52. Utility of Serum and Urine uPAR Levels for Diagnosis of Breast Cancer

Soydinc H. O., Duranyildiz D., Guney N., Derin D., Yasasever V.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.6, ss.2887-2889, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

53. Markers of Bone Metastases in Breast and Lung Cancers

Bilgin E., Yasasever V., Soydinc H. O., Yasasever C., Ozturk N., Duranyildiz D.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.13, sa.9, ss.4331-4334, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

54. Angiogenic factors in small veil lung cancer (VEGF, VEGFR-1, VEGFR-2)

OĞUZ SOYDİNÇ H., DURANYILDIZ H. D., Bilgin E., TAŞ F., Yasasever V.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.27, sa.2, ss.55-61, 2012 (ESCI) Sürdürülebilir Kalkınma

55. Lack of Diagnostic Potential of Dickkopf-1 in Colon and Rectum Cancers

Soydinc H. O., Duranyildiz D., Camlica H., Oral E. N., Yasasever V.

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.12, sa.12, ss.3187-3189, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

56. Hematological parameters in lung cancer

SERİLMEZ M., OĞUZ SOYDİNÇ H., Camlica H., Topuz E., DURANYILDIZ H. D.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.25, sa.3, ss.87-92, 2010 (ESCI, Scopus) Sürdürülebilir Kalkınma

57. Serum levels of angiogenic factors in early breast cancer remain close to normal

Duranyildiz D., Camlica H., Soydinc H. O., Derin D., Yasasever V.

BREAST , cilt.18, sa.1, ss.26-29, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

58. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma

Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.

MEDICAL ONCOLOGY , cilt.25, sa.4, ss.431-436, 2008 (SCI-Expanded, Scopus)

59. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases

Tas F., Duranyildiz D., Oguz H., Camlica H., Yasasever V., Topuz E.

MEDICAL ONCOLOGY , cilt.25, sa.3, ss.346-349, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer

Guney N., Soydinc H. O., Derin D., Tas F., Camlica H., Duranyildiz D., et al.

MEDICAL ONCOLOGY , cilt.25, sa.2, ss.194-200, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

61. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer

Tas F., Duranyildiz D., Soydinc H. O., Cicin I., Selam M., Uygun K., et al.

CANCER CHEMOTHERAPY AND PHARMACOLOGY , cilt.61, sa.5, ss.721-725, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

62. The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer

Camlica H., Duranyildiz D., Oguz H., Oral E. N., Yasasever V.

PATHOLOGY & ONCOLOGY RESEARCH , cilt.14, sa.1, ss.79-83, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

63. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer

Derin D., Soydinc H. O., Guney N., Tas F., Camlica H., Duranyildiz D., et al.

LUNG CANCER , cilt.59, sa.2, ss.240-245, 2008 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

64. Macrophage migration inhibitory factor in cancer

Yasasever V., Camlica H., Duranyildiz D., Oguz H., Tas F., Dalay N.

CANCER INVESTIGATION , cilt.25, sa.8, ss.715-719, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

65. Serum IL-8 and IL-12 levels in breast cancer

Derin D., SOYDINC H. O., Güney N., Tas F., Çamlıca H., Duranyıldız D., et al.

MEDICAL ONCOLOGY , cilt.24, sa.2, ss.163-168, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients

Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.

MELANOMA RESEARCH , cilt.16, sa.5, ss.405-411, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

67. Serum vascular endothelial growth factor (VEGF) and Bcl-2 levels in advanced stage non-small cell lung cancer

Tas F., Duranyıldız D., OĞUZ H., Çamlıca H., Yasasever V., Topuz E.

CANCER INVESTIGATION , cilt.24, sa.6, ss.576-580, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer

Tas F., DURANYILDIZ D., Oguz H., CAMLICA H., YASASEVER V., TOPUZ E.

CANCER INVESTIGATION , cilt.24, sa.5, ss.492-496, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

69. Molecular detection of squamous cell carcinoma antigen transcripts in peripheral blood of cancer patients

Buyru N., Tigli H., Duranyildiz D., Dalay N.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE , cilt.44, sa.5, ss.538-541, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma

70. Matriks Metalloproteinazlar ve Akciğer Kanseri

OĞUZ H., Çamlıca H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., YASASEVER F. V., et al.

TÜRK ONKOLOJİ DERGİSİ , cilt.21, sa.2, ss.53-56, 2006 (Hakemli Dergi) Sürdürülebilir Kalkınma

71. Serum and urine survivin levels in breast cancer

Güney N., SOYDINE H., DEFIN D., Tas F., Çamlıca H., Duranyıldız D., et al.

MEDICAL ONCOLOGY , cilt.23, sa.3, ss.335-339, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

72. Matrix metalloproteinases and lung cancer

OĞUZ SOYDİNÇ H., Camlica H., DURANYILDIZ H. D., KAYTAN SAĞLAM E., TAŞ F., Yasasever V., et al.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.21, sa.2, ss.53-56, 2006 (ESCI) Sürdürülebilir Kalkınma

73. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma

TAS F., DURANYILDIZ D., OGUZ H., DISCI R., KURUL S., Yasasever V., et al.

MEDICAL ONCOLOGY , cilt.22, sa.1, ss.39-44, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer

TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., et al.

MEDICAL ONCOLOGY , cilt.22, sa.4, ss.353-358, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

75. The value of serum levels of IL-6, TNF-alpha, and erythropoietin in metastatic malignant melanoma

TAS F., OGUZ H., ARGON A., DURANYILDIZ D., CAMLICA H., Yasasever V., et al.

MEDICAL ONCOLOGY , cilt.22, sa.3, ss.241-246, 2005 (SCI-Expanded, Scopus)

76. The value of serum Bcl-2 levels in advanced lung cancer patients

TAS F., DURANYILDIZ D., OGUZ H., CAMLICA H., ORAL E., Yasasever V., et al.

MEDICAL ONCOLOGY , cilt.22, sa.2, ss.139-143, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

77. MALIGNANT MELANOMA AND SURVIVIN

Oguz H., DURANYILDIZ H. D., Camlica H., TAŞ F., Yasasever V., Topuz E.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.20, sa.1, ss.27-29, 2005 (ESCI)

78. Serum bcl-2 and survivin levels in melanoma

TAS F., DURANYILDIZ D., ARGON A., OGUZ H., CAMLICA H., Yasasever V., et al.

MELANOMA RESEARCH , cilt.14, sa.6, ss.543-546, 2004 (SCI-Expanded, Scopus)

79. Is Free Beta Human Chorionic Gonadotropin A Useful Tumor Marker in Lung Cancer?

ORAL E. N., KİZİR A., DURANYILDIZ D., Çamlıca H., DEMOKAN S., YASASEVER V., et al.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.19, sa.5, ss.337-340, 2004 (Hakemli Dergi) Sürdürülebilir Kalkınma

80. Protein 90K, ICAM1, P-Selectin and Neopterin Levels in Turkish Breast Cancer Patients

YASASEVER F. V., DURANYILDIZ H. D., DİNÇER M., Çamlıca H., DEMOKAN İSHAKOĞLU S., DALAY M. N.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.19, sa.3, ss.199-205, 2004 (Hakemli Dergi) Sürdürülebilir Kalkınma

81. Detection of circulating melanoma cells by a two-marker polymerase chain reaction assay in relation to therapy.

Bitisik O., Camlica H., Duranyildiz D., Tas F., Kurul S., Dalay N.

Journal of biochemistry and molecular biology , cilt.36, sa.2, ss.173-8, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

82. Age Adjusted PSA and Serum Prostate-Specific Antigem Levels in the Turkish Population

Çamlıca H., DURANYILDIZ H. D., YASASEVER F. V., DALAY M. N.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.17, sa.3, ss.147-152, 2002 (Hakemli Dergi)

83. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma.

Meral R., Duranyildiz D., Tas F., Camlica H., Yasasever V., Kurul S., et al.

Melanoma research , cilt.11, sa.6, ss.627-32, 2001 (SCI-Expanded, Scopus)

84. Serum Total Antioxidant Levels are Loe in Cancer Patients

YASASEVER F. V., DURANYILDIZ H. D., DİNÇER M., Çamlıca H., Oral E. N., CENGİZ M., et al.

RESEARCH COMMUNICATIONS IN BIOCHEMISTRY AND CELLULAR AND MOLECULAR BIOLOGY , cilt.4, ss.277-284, 2001 (Hakemli Dergi) Sürdürülebilir Kalkınma

85. Serum c-erb B2 oncoprotein levels are elevated in recurrent and metastatic breast cancer

Yasasever V., Dincer M., Camlica H., Duranyildiz D., Dalay N.

CLINICAL BIOCHEMISTRY , cilt.33, sa.4, ss.315-317, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

86. Serum NSE levels in the Turkish population

Yasasever V., Meral R., Camlica H., Duranyildiz D., Dalay N.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.14, sa.3, ss.35-40, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

87. Diagnostic value of the PSA subfractions, acid phosphatase and creatine kinase isoenzymes in prostate cancer

Duranyildiz D., Camlica H., Yasasever V., Ozcan F., Dalay N.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.14, sa.1, ss.39-46, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

88. Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients

Yasasever V., Dincer M., Camlica H., Duranyildiz D., Dalay N.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY , cilt.18, sa.5, ss.397-399, 1997 (SCI-Expanded) Sürdürülebilir Kalkınma

89. Serum neu Oncoproein Levels in Breast Cancer

YASASEVER F. V., DURANYILDIZ H. D., YAZICI ÖZBEK H., ONAT H., DALAY M. N.

JOURNAL OF TUMOR MARKER ONCOLOGY , cilt.7, sa.2, ss.33-43, 1992 (Hakemli Dergi) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 26

1. Do salivary cullin7 gene expression and protein levels provide advantages over plasma levels in diagnosing breast cancer?

Tilgen Yasasever C., Duranyıldız H. D., Bademler S., Oğuz Soydinç H.

49th FEBS Congress, İstanbul, Türkiye, 5 - 09 Temmuz 2025, ss.232, (Özet Bildiri)

2. Prognostic Importance of BRAF and PTEN Proteins in Patients with Malignant Melanoma

Bilgin Doğru E., Tilgen Yasasever C., Serilmez M., Taş F., Duranyıldız H. D., Oğuz Soydinç H.

IX. INTERNATIONAL CONGRESS OF MOLECULAR MEDICINE “MOLECULAR MEDICINE IN LIFE SCIENCES”, İstanbul, Türkiye, 18 - 20 Aralık 2023, ss.1, (Özet Bildiri)

3. MEME KANSERİNDE SERUM DOUBLECORTİN-LİKE KİNASE 1DÜZEYLERİ

ÖZTÜRK N., KARADENİZ E., DURANYILDIZ H. D., SERİLMEZ M., OĞUZ SOYDİNÇ H., ÖZTÜRK G., et al.

UluslararasıLaboratuvar Tıbbıve XX. Ulusal KlinikBiyokimya Kongresi, Türkiye, 25 - 26 Aralık 2020, (Özet Bildiri)

4. The biological role of AKT serine/threonine kinase 2 in lung cancer

Serilmez M., Karaman S., Soydinc H. O., Yasasever C., Bilgin E., Duranyildiz D., et al.

ECCO European Cancer Congress, Amsterdam, Hollanda, 27 - 30 Ocak 2017, cilt.72, (Özet Bildiri) Sürdürülebilir Kalkınma

5. Do serum nestin levels have a diagnostic effect in patients with colorectal cancer?

KARABULUT S., Serilmez M., Soydinc H., Duranyildiz D.

41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Türkiye, 3 - 08 Eylül 2016, cilt.283, ss.115, (Özet Bildiri) Sürdürülebilir Kalkınma

6. The role of cytokines and adhesion molecules in hepatocellular carcinoma to predict survival

Akyuz F., Iliaz R., AKYUZ U., Duranyildiz D., Serilmez M., Karaca C., et al.

66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri)

7. Serum MCP-1 in pancreatic adenocarcinoma

Soydinc H., Serilmez M., Karabulut S., Duranyildiz D., Yasasever V.

40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Almanya, 4 - 09 Temmuz 2015, cilt.282, ss.261, (Özet Bildiri)

8. Serum NEDD9 levels may have prognostic roles in patients with gastric cancer

Duranyildiz D., Serilmez M., Soydinc H. O., Karabulut S., Yasasever V.

40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Almanya, 4 - 09 Temmuz 2015, cilt.282, ss.253-254, (Özet Bildiri) Sürdürülebilir Kalkınma

9. Do serum nectin-2 levels have a prognostic effect in patients with colorectal cancer?

Serilmez M., Duranyildiz D., Soydinc H., Karabulut S., Yasasever V.

40th Congress of the Federation-of-European-Biochemical-Societies (FEBS) - The Biochemical Basis of Life, Berlin, Almanya, 4 - 09 Temmuz 2015, cilt.282, ss.257, (Özet Bildiri) Sürdürülebilir Kalkınma

10. DO THE MATRIX METALLOPROTEASES HAVE ANY EFFECT ON EPITHELIAL OVARIAN TUMORS?

BİLGİN DOĞRU E., Serilmez M., ÖZTÜRK N., DURANYILDIZ H. D., YASASEVER F. V.

IFCC WorldLAB Istanbul 2014, İstanbul, Türkiye, 22 - 26 Haziran 2014, ss.371, (Tam Metin Bildiri)

11. OMENTIN LEVELS IN COLON CANCER

Serilmez M., Ciftci R., BİLGİN DOĞRU E., DURANYILDIZ H. D.

IFCC WorldLAB Istanbul 2014, İstanbul, Türkiye, 22 - 26 Haziran 2014, ss.464, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

12. THE IMPORTANCE OF CEA IN COLON CANCER

Aksit E., TİLGEN YASASEVER C., ÖZTÜRK N., DURANYILDIZ H. D., YASASEVER F. V.

IFCC WorldLab, İstanbul, Türkiye, 22 - 26 Haziran 2014, ss.363, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

13. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) cud vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.

KARABULUT S., Tastekin D., CIFTCI R., Tambas M., DAGOGLU N., Guveil M. E., et al.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) Sürdürülebilir Kalkınma

14. Clinical significance of serum caveolin-1 levels in melanoma.

Tastekin D., KARABULUT S., DURANYILDIZ D., Tas F.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)